1238 related articles for article (PubMed ID: 25765696)
1. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
[TBL] [Abstract][Full Text] [Related]
2. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
[TBL] [Abstract][Full Text] [Related]
3. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
Shimada YJ; Cannon CP; Liu Y; Wilson C; Kupfer S; Menon V; Cushman WC; Mehta CR; Bakris GL; Zannad F; White WB;
Am Heart J; 2016 May; 175():18-27. PubMed ID: 27179720
[TBL] [Abstract][Full Text] [Related]
4. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
[TBL] [Abstract][Full Text] [Related]
5. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
6. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.
Sharma A; Vaduganathan M; Ferreira JP; Liu Y; Bakris GL; Cannon CP; White WB; Zannad F
J Am Heart Assoc; 2020 Jan; 9(1):e012797. PubMed ID: 31902327
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V
Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
[TBL] [Abstract][Full Text] [Related]
9. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Sharma A; Cannon CP; White WB; Liu Y; Bakris GL; Cushman WC; Zannad F
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29769203
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
[TBL] [Abstract][Full Text] [Related]
11. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
[TBL] [Abstract][Full Text] [Related]
13. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Tardif JC; McMurray JJ; Klug E; Small R; Schumi J; Choi J; Cooper J; Scott R; Lewis EF; L'Allier PL; Pfeffer MA;
Lancet; 2008 May; 371(9626):1761-8. PubMed ID: 18502300
[TBL] [Abstract][Full Text] [Related]
14. EXAMINE: targeting risk and treatment in diabetes.
Hülsmann M; Pacher R; Neuhold S
Lancet; 2015 Oct; 386(10002):1444-5. PubMed ID: 26466043
[No Abstract] [Full Text] [Related]
15. EXAMINE: targeting risk and treatment in diabetes.
Derosa G; Maffioli P
Lancet; 2015 Oct; 386(10002):1443. PubMed ID: 26466042
[No Abstract] [Full Text] [Related]
16. EXAMINE: targeting risk and treatment in diabetes.
Riche DM; Davis C
Lancet; 2015 Oct; 386(10002):1443-4. PubMed ID: 26466041
[No Abstract] [Full Text] [Related]
17. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
Bergmark BA; Cannon CP; White WB; Jarolim P; Liu Y; Bonaca MP; Zannad F; Morrow DA
Diabetes Obes Metab; 2017 Jul; 19(7):962-969. PubMed ID: 28195387
[TBL] [Abstract][Full Text] [Related]
18. Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.
Jarolim P; White WB; Cannon CP; Gao Q; Morrow DA
Diabetes Care; 2018 Jul; 41(7):1510-1515. PubMed ID: 29848776
[TBL] [Abstract][Full Text] [Related]
19. EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
White WB; Kupfer S; Zannad F
Lancet; 2015 Oct; 386(10002):1445. PubMed ID: 26466044
[No Abstract] [Full Text] [Related]
20. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial.
Ferreira JP; Mehta C; Sharma A; Nissen SE; Rossignol P; Zannad F
BMC Med; 2020 Jun; 18(1):165. PubMed ID: 32493335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
